SonoThera secures $186 million to advance non-viral gene-therapy platform
read at Endpoints ↗DealPositive
SonoThera, the winner of the Endpoints 11 2026 competition, announced a fresh financing round to push its non-viral gene-therapy technology forward.
The company raised a total of $186 million, with contributions from a roster of investors that includes Vida Ventures, ARCH Ventures Partners, Illumina Ventures, Leaps by Bayer, Johnson & Johnson Innovation and Eli Lilly.
Led by CEO Kenneth Greenberg and CSO Steve Feinstein, SonoThera is based in San Francisco and plans to use the capital to further develop its platform and move candidates toward clinical testing.
source
This writeup was produced by pharmadog from original reporting by Endpoints.
Original headline: “Endpoints 11 2026 winner SonoThera has a new approach to non-viral gene therapy”
read at Endpoints ↗85 words · retrieved 1h ago
comments(0)
5-min edit window · permanent after that